targeted alpha therapy

Representative image: A sterile radiopharmaceutical manufacturing cleanroom with shielded processing equipment and sealed vials, illustrating how Niowave’s Michigan Actinium-225 facility could support the next phase of targeted cancer therapy supply.

Pharma & Biotech

Can Niowave’s Michigan facility ease the Actinium-225 bottleneck in cancer therapy?

by Pallavi Madhiraju
May 24, 2026
0 Comments

Find out how Niowave’s $75m Michigan facility could reshape Actinium-225 supply for targeted cancer therapies.

Pharma & Biotech

What TAG1’s Lead-212 supply deal with Dana-Farber reveals about the future of radiopharmaceutical oncology

by Pallavi Madhiraju
March 8, 2026
0 Comments

TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.